$MDGN (Medgenics, Inc.)

$MDGN {{ '2016-06-06T18:06:13+0000' | timeago}} • Announcement

$MDGN said it has entered into a collaboration with Kyowa Hakko Kirin for the development and commercialization of Kyowa's first-in-class anti-LIGHT monoclonal antibody. The anti-LIGHT monoclonal antibody is a Phase 2-ready biologic with available clinical supply.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-10T12:58:24+0000' | timeago}} • Announcement

$BIIB appointed Amy Chevalier Efantis as VP of Government Affairs, effective July 17. Efantis brings more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company's federal and state government affairs activities from $BIIB's Washington, D.C., office.

$CRL {{ '2017-07-05T12:50:22+0000' | timeago}} • Announcement

$CRL appointed $ALXN EVP Dr Martin Mackay to its BoD.  As a member of the board, he will serve on the Corporate Governance and Nominating Committee and the Science and Technology Committee.

$ACOR {{ '2017-06-29T20:59:19+0000' | timeago}} • Announcement

$ACOR submits New Drug Application (NDA) to FDA for Inbrija, a potential therapy for patients with Parkinson’s disease. Acorda Therapeutics plans to file a Marketing Authorization Application (MAA) in Europe for Inbrija by the end of 2017.

$BIIB {{ '2017-06-28T12:10:03+0000' | timeago}} • Announcement

Pharma company $BIIB has appointed Catherine Steele as SVP of Corporate Affairs, effective July 17, 2007. Most recently, Steele served Novartis Pharmaceuticals as Global Head of Communications and Patient Relations. She began her biopharma career with Roche, where she worked more than a decade.

$ALXN {{ '2017-06-23T12:15:29+0000' | timeago}} • Announcement

$ALXN said it received positive opinion from the Committee for Medicinal Products for Human Use to extend the therapeutic indication for Soliris to include the treatment of refractory generalized myasthenia gravis in patients who are ‘anti-acetylcholine receptor antibody-positive’. A final decision from the European Commission is expected in 3Q17.

$ALGN {{ '2017-06-16T12:42:31+0000' | timeago}} • Announcement

Standard & Poor's will add $ALGN to the S&P 500 Index after the close of trading on June 16, 2017. Align will be added to the S&P 500 GICS Health Care Supplies Sub-Industry index.

$BIIB {{ '2017-06-14T14:06:09+0000' | timeago}} • Announcement

$BIIB appointed Jean-Paul Kress as EVP and President, International, and Head of Global Therapeutic Operations, effective June 19, 2017. Kress will have direct responsibility for worldwide commercial operations outside the US and will also oversee the Rare and Specialty Disease Asset teams.

$BIIB {{ '2017-06-13T21:38:43+0000' | timeago}} • Announcement

$BIIB said Paul Clancy, EVP, Finance & CFO will leave the organization to join another biopharmaceutical company. Clancy will remain at the company through 2Q and assist with the transition. CAO Greg Covino will serve as the company's interim Principal Financial Officer as the company conducts a search for a new CFO.

$ALXN {{ '2017-06-13T21:27:41+0000' | timeago}} • Announcement

$ALXN appointed Paul Clancy as CFO effective July 31, 2017. Clancy will succeed Dave Anderson, who will continue to serve as CFO until July 31, 2017. To ensure a smooth transition, Anderson will then become a Senior Advisor to the CEO and will remain with the company until the end of August.

$ACOR {{ '2017-06-06T13:47:37+0000' | timeago}} • Announcement

$ACOR presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson's Disease Rating Scale - Part III (UPDRS III) in people with Parkinson's experiencing OFF periods.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$ALXN {{ '2017-06-01T20:48:22+0000' | timeago}} • Announcement

$ALXN announced key additions to its executive leadership team effective June 5, 2017. Reporting to CEO Ludwig Hantson will be: John Orloff, M.D., EVP, Head of Research & Development, Anne-Marie Law, EVP, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., EVP, Chief Compliance Officer.

$ALGN {{ '2017-06-01T12:21:15+0000' | timeago}} • Announcement

$ALGN announced the opening of a new Invisalign treatment planning facility in Chengdu, China. The state of the art facility is the company's first manufacturing operations in China and represents the company's commitment to geographic expansion and investment in the Asia Pacific region.

Recent Transcripts

BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
CRME (Cardiome Pharma Corp.)
Monday, May 15 2017 - 8:30pm
CGIX (Cancer Genetics, Inc.)
Friday, May 12 2017 - 1:00pm
ALIM (Alimera Sciences, Inc.)
Tuesday, May 9 2017 - 12:00pm
BCRX (BioCryst Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 3:00pm
CSII (Cardiovascular Systems Inc.)
Wednesday, May 3 2017 - 8:45pm
ALGN (Align Technology Inc.)
Thursday, April 27 2017 - 8:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
CGIX (Cancer Genetics, Inc.)
Thursday, March 23 2017 - 1:00pm
CRME (Cardiome Pharma Corp.)
Tuesday, March 7 2017 - 9:30pm
ALIM (Alimera Sciences, Inc.)
Thursday, March 2 2017 - 3:00pm
BCRX (BioCryst Pharmaceuticals, Inc.)
Monday, February 27 2017 - 2:00pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, February 16 2017 - 3:00pm
ALKS (Alkermes plc)
Wednesday, February 15 2017 - 1:30pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, February 14 2017 - 1:30pm
ALGN (Align Technology Inc.)
Tuesday, January 31 2017 - 9:00pm
BIIB (Biogen Inc.)
Thursday, January 26 2017 - 1:00pm

AlphaGraphics you may like